ArticleVascular health and risk management2025
Platelet-to-Hemoglobin Ratio in Predicting Major Adverse Cardiovascular Events After Coronary Artery Bypass Grafting.
Article in Vascular health and risk management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Coronary artery bypass grafting (CABG) is widely recognized as the gold standard treatment for patients with complex coronary artery disease (CAD). The identification of reliable hematologic predictors for major adverse cardiovascular events (MACE) after CABG remains limited. In recent years, the platelet-to-hemoglobin ratio (PHR) has emerged as a promising prognostic marker in various cardiovascular conditions and malignancies. This study investigated the prognostic value of the PHR for predicting in-hospital and short-term adverse outcomes after CABG. Patients and Methods: This retrospective cohort study included 1672 Chinese patients who underwent isolated CABG surgery between 2015 and 2021. PHR was calculated as platelet count (×10 Results: In our study, individuals with elevated PHR levels were more likely to experience 3P-MACE and stroke. After propensity matching, the incidence of 3P-MACE was 5.7% in the high PHR group (PHR≥1.890) and 1.5% in the low PHR group ( Conclusion: Elevated PHR (≥1.890) was independently associated with postoperative 3P-MACE, reflecting the integrated effects of thrombosis and anemia risk. Although PHR demonstrated modest discrimination as a single variable, its integration into a multivariable nomogram improved predictive accuracy. These findings are hypothesis-generating and future multicenter, prospective validation studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.